TW200613012A - Sustained-release composition, process for producing the same and use of the same - Google Patents
Sustained-release composition, process for producing the same and use of the sameInfo
- Publication number
- TW200613012A TW200613012A TW094121375A TW94121375A TW200613012A TW 200613012 A TW200613012 A TW 200613012A TW 094121375 A TW094121375 A TW 094121375A TW 94121375 A TW94121375 A TW 94121375A TW 200613012 A TW200613012 A TW 200613012A
- Authority
- TW
- Taiwan
- Prior art keywords
- same
- sustained
- release composition
- average molecular
- molecular weight
- Prior art date
Links
- 238000013268 sustained release Methods 0.000 title abstract 3
- 239000012730 sustained-release form Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 title 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 abstract 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 abstract 2
- 239000013543 active substance Substances 0.000 abstract 1
- 229920001577 copolymer Polymers 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 235000014655 lactic acid Nutrition 0.000 abstract 1
- 239000004310 lactic acid Substances 0.000 abstract 1
- 230000000149 penetrating effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Gynecology & Obstetrics (AREA)
- Urology & Nephrology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2004196831 | 2004-07-02 | ||
| JP2004267537 | 2004-09-14 | ||
| JP2004296635 | 2004-10-08 | ||
| JP2005023261 | 2005-01-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW200613012A true TW200613012A (en) | 2006-05-01 |
Family
ID=34971927
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW094121375A TW200613012A (en) | 2004-07-02 | 2005-06-27 | Sustained-release composition, process for producing the same and use of the same |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20080118545A1 (zh) |
| EP (1) | EP1765295B2 (zh) |
| JP (1) | JP5601749B2 (zh) |
| CA (1) | CA2571583C (zh) |
| ES (1) | ES2391460T5 (zh) |
| TW (1) | TW200613012A (zh) |
| WO (1) | WO2006004167A1 (zh) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101563068B (zh) * | 2006-12-18 | 2013-03-20 | 武田药品工业株式会社 | 缓释组合物和其制备方法 |
| UY33127A (es) * | 2009-12-22 | 2011-07-29 | Takeda Pharmaceutical | Formulación de liberación sostenida |
| US9205577B2 (en) * | 2010-02-05 | 2015-12-08 | Allergan, Inc. | Porogen compositions, methods of making and uses |
| US9138309B2 (en) | 2010-02-05 | 2015-09-22 | Allergan, Inc. | Porous materials, methods of making and uses |
| US11202853B2 (en) * | 2010-05-11 | 2021-12-21 | Allergan, Inc. | Porogen compositions, methods of making and uses |
| US20120270078A1 (en) * | 2011-04-08 | 2012-10-25 | Glenn Godden | Liquid Battery Formed from Encapsulated Components |
| US9517210B2 (en) | 2012-07-12 | 2016-12-13 | Takeda Pharmaceutical Company Limited | Method for producing microcapsule powder |
| EP3131532A1 (de) | 2014-04-16 | 2017-02-22 | Veyx-Pharma GmbH | Veterinärpharmazeutische zusammensetzung und deren verwendung |
| TW201618783A (zh) | 2014-08-07 | 2016-06-01 | 艾森塔製藥公司 | 以布魯頓(Bruton)氏酪胺酸激酶(BTK)佔據和BTK再合成速率為基礎之治療癌症、免疫和自體免疫疾病及發炎性疾病之方法 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60100516A (ja) * | 1983-11-04 | 1985-06-04 | Takeda Chem Ind Ltd | 徐放型マイクロカプセルの製造法 |
| EP0190833B1 (en) * | 1985-02-07 | 1991-03-27 | Takeda Chemical Industries, Ltd. | Method for producing microcapsule |
| JP2551756B2 (ja) * | 1985-05-07 | 1996-11-06 | 武田薬品工業株式会社 | ポリオキシカルボン酸エステルおよびその製造法 |
| MY107937A (en) * | 1990-02-13 | 1996-06-29 | Takeda Chemical Industries Ltd | Prolonged release microcapsules. |
| DE69129770T2 (de) * | 1990-04-13 | 1998-11-19 | Takeda Chemical Industries Ltd | Biologisch abbaubare hochmolekulare Polymere, ihre Herstellung und ihre Verwendung |
| ES2110573T3 (es) * | 1992-08-07 | 1998-02-16 | Takeda Chemical Industries Ltd | Produccion de microcapsulas de farmacos solubles en agua. |
| JP3277342B2 (ja) * | 1992-09-02 | 2002-04-22 | 武田薬品工業株式会社 | 徐放性マイクロカプセルの製造法 |
| NZ260909A (en) * | 1993-07-05 | 1995-04-27 | Takeda Chemical Industries Ltd | Production of sustained release preparation by allowing a water-soluble polypeptide to permeate into a biodegradable matrix in an aqueous solution |
| JPH08259460A (ja) * | 1995-01-23 | 1996-10-08 | Takeda Chem Ind Ltd | 徐放性製剤の製造法 |
| TW448055B (en) * | 1995-09-04 | 2001-08-01 | Takeda Chemical Industries Ltd | Method of production of sustained-release preparation |
| CA2192773C (en) * | 1995-12-15 | 2008-09-23 | Hiroaki Okada | Production of sustained-release preparation for injection |
| JPH09221420A (ja) * | 1995-12-15 | 1997-08-26 | Takeda Chem Ind Ltd | ヒドロキサム酸類の徐放性製剤 |
| CA2192782C (en) † | 1995-12-15 | 2008-10-14 | Nobuyuki Takechi | Production of microspheres |
| US6419961B1 (en) * | 1996-08-29 | 2002-07-16 | Takeda Chemical Industries, Ltd. | Sustained release microcapsules of a bioactive substance and a biodegradable polymer |
| EP0839525B1 (en) * | 1996-10-31 | 2004-08-04 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
| US6740634B1 (en) * | 1998-01-16 | 2004-05-25 | Takeda Chemical Industries, Ltd. | Sustained release compositions, process for producing the same and utilization thereof |
| ATE322513T1 (de) * | 2000-08-07 | 2006-04-15 | Wako Pure Chem Ind Ltd | Milchsäurepolymer und verfahren zu dessen herstellung |
| TWI225416B (en) * | 2001-06-29 | 2004-12-21 | Takeda Chemical Industries Ltd | Sustained-release composition and process for producing the same |
| TW200526267A (en) * | 2001-06-29 | 2005-08-16 | Takeda Chemical Industries Ltd | Controlled release composition and method of producing the same |
| JP3902518B2 (ja) * | 2001-06-29 | 2007-04-11 | 武田薬品工業株式会社 | 徐放性組成物用乳酸−グリコール酸重合体の製造法 |
| CA2471521C (en) * | 2001-12-26 | 2010-11-02 | Takeda Chemical Industries, Ltd. | Novel microsphere and method for production thereof |
| CA2490351C (en) * | 2002-06-25 | 2011-11-01 | Takeda Pharmaceutical Company Limited | Process for producing sustained-release composition |
| TW200529890A (en) * | 2004-02-10 | 2005-09-16 | Takeda Pharmaceutical | Sustained-release preparations |
-
2005
- 2005-06-27 TW TW094121375A patent/TW200613012A/zh unknown
- 2005-06-30 EP EP05758111.8A patent/EP1765295B2/en not_active Expired - Lifetime
- 2005-06-30 WO PCT/JP2005/012517 patent/WO2006004167A1/en not_active Ceased
- 2005-06-30 JP JP2006554385A patent/JP5601749B2/ja not_active Expired - Lifetime
- 2005-06-30 US US11/631,094 patent/US20080118545A1/en not_active Abandoned
- 2005-06-30 CA CA2571583A patent/CA2571583C/en not_active Expired - Fee Related
- 2005-06-30 ES ES05758111.8T patent/ES2391460T5/es not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JP5601749B2 (ja) | 2014-10-08 |
| ES2391460T5 (es) | 2015-10-27 |
| CA2571583A1 (en) | 2006-01-12 |
| ES2391460T3 (es) | 2012-11-27 |
| US20080118545A1 (en) | 2008-05-22 |
| WO2006004167A1 (en) | 2006-01-12 |
| EP1765295A1 (en) | 2007-03-28 |
| JP2008505057A (ja) | 2008-02-21 |
| CA2571583C (en) | 2013-04-30 |
| EP1765295B2 (en) | 2015-09-09 |
| EP1765295B1 (en) | 2012-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7584178B2 (ja) | 治療剤の制御放出のための埋込み可能なデポー | |
| CY1111708T1 (el) | Συνθεση ελεγχομενης απελευθερωσης και μεθοδος παρασκευης αυτης | |
| MXPA03011440A (es) | Composicion de liberacion sostenida y proceso para producirla. | |
| WO2003007782A3 (en) | Biodegradable injectable implants and related methods of manufacture and use | |
| MX2009001230A (es) | Implantes subcutaneos que liberan un principio activo durante un periodo de tiempo extendido. | |
| TW200613012A (en) | Sustained-release composition, process for producing the same and use of the same | |
| WO2004060405A3 (en) | Tissue reactive compounds and compositions and uses thereof | |
| GB0202233D0 (en) | Bioresorbable polymers | |
| RU2012157244A (ru) | Жидкотекучие композиции для инъекций, включающие бупренорфин | |
| ATE321533T1 (de) | Pharmazeutische zusammensetzungen mit verzögerter freisetzung für die parenterale applikation von hydrophilen wirkstoffen | |
| TN2009000197A1 (en) | Sustained - release composition and method for producing the same | |
| BRPI0511224A (pt) | método para preparar uma composição contendo antagonistas de opióides, produto contendo antagonistas de opióides, composição contendo antagonistas de opióides, formulação de dosagem injetável, kit, método para prevenir ou tratar um efeito colateral associado com um opióide num paciente, e para tratar ou impedir dor num paciente | |
| EP1693054A3 (en) | Lactic acid polymer and process for producing the same | |
| JPS6413034A (en) | Selectively biodegradable polymer blend | |
| ATE360413T1 (de) | Zusammensetzungen mit verzögerter freigabe, verfahren zu deren herstellung und verwendung | |
| IL152479A (en) | Pharmaceutical form for giving peptides, methods for making and using it | |
| JPH02503315A (ja) | 機能的に活性な組成物の徐放性を有する固体形態物の製造法 | |
| WO2001093911A3 (en) | Macromolecular drug complexes and compositions containing the same | |
| DE502005010427D1 (de) | Physiologisch aktive zusammensetzung gegen diabetes | |
| AR033918A1 (es) | Composicion para acelerar la soldadura de una fractura osea | |
| NO20052505L (no) | Ny bruk av dextran-sulfat | |
| WO2006107311A3 (en) | Biocompatible polymeric vesicles self assembled from triblock copolymers | |
| AR034044A1 (es) | Composicion para el tratamiento reconstituyente en enfermedades de cartilago | |
| WO2004037311A3 (en) | Device and methods for sequential, regional delivery of multiple cytotoxic agents | |
| BR9706960A (pt) | Polìmeros com estado fìsico e condição de bioerosão controlados |